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earning From a Real-World
nalysis of Implantable
ardioverter-Defibrillator
ecipients
omorbidities Matter*
umeet S. Chugh, MD, FACC,
yndaron Reinier, PHD,
ric C. Stecker, MD, MPH
ortland, Oregon
ith a 90% near-instantaneous mortality rate, sudden
ardiac arrest may be the human disease condition with the
ost potential of benefiting from preventive interventions.
he implantable cardioverter-defibrillator (ICD), one of the
ore remarkable therapeutic advances of the 20th century,
s currently the most effective preventive intervention for
udden cardiac death (SCD). The majority of prospective
econdary and primary prevention multicenter trials evalu-
ting the ICD showed a significant beneficial effect on
verall mortality, with several meta-analyses observing a
lear net benefit compared with medical therapy (1–8).
See page 2408
ccordingly, guidelines have been written, indications have
een established, and health care providers are already
aring for a rapidly burgeoning population of ICD recipi-
nts, particularly for primary prevention indications (9).
owever, methodology for risk stratification has not devel-
ped at the same pace. In the randomized primary preven-
ion ICD trials, the vast majority (60% to 80%) of ICD
ecipients did not require device therapies during an inter-
ediate follow-up period of 3 to 5 years (1,7). Furthermore,
ecent population-based analyses indicate that only a mi-
ority of SCD cases have severely decreased left ventricular
jection fraction (LVEF); most have either normal LVEF
r mildly to moderately decreased LVEF (10,11). Although
he LVEF is a reasonable predictor of overall mortality, it is
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.c
From the Cardiac Arrhythmia Center, Division of Cardiovascular Medicine,
regon Health and Science University, Portland, Oregon.nlikely to be an efficient risk determinant, especially when
sed as the sole criterion for primary prevention ICD
mplantation (12). Clearly, methods of risk stratification
eed to be enhanced significantly, and this is an area of
ctive investigation, but developments will take some time.
n the meantime, much can be learned from ongoing
valuations of large groups of ICD recipients.
In this issue of the Journal, Lee et al. (13) have reported
heir observations from such a “real-world” evaluation of
pproximately 2,500 ICD recipients with a follow-up of at
east 2 years, using a province-wide administrative database
n Ontario, Canada. There are several interesting findings,
he first being that comorbidities were significant determi-
ants of mortality in ICD recipients. The risk conferred by
omorbidities was incrementally related to number of co-
orbidities. Although not unexpected, because elevated
udden arrhythmic death risk, particularly in an aging
opulace, is likely to coexist with other morbidities, there
as been a lack of such data among ICD recipients. Among
ther populations, comorbidities such as peripheral vascular
isease, chronic obstructive pulmonary disease, and renal
isease are established predictors of overall mortality, and
CD recipients are no exception (14). Although the distinc-
ion between less versus more advanced diabetes mellitus is
ften not made, the effect of this condition on both
rrhythmic and nonarrhythmic mortality is a recurring
heme (15). These findings underscore the need for a
eightened awareness of the likely possibility of managing
hese conditions in ICD patients. However, they should not
e construed as direct evidence that these specific comor-
idities should influence our criteria for ICD implantation.
ost of the analysis focuses on the ICD group alone. Since
etailed comparisons were not made and the control group
s not convincingly derived from a similar population, this
tudy should not be used to evaluate the decision for ICD
mplantation. From an administrative database, without
vailability of ICD events and therapies, we cannot be sure
bout the specific contributions of comorbidities to arrhyth-
ic versus nonarrhythmic mortality. Despite the improve-
ent in response times, community-based studies of pri-
ary cardiac arrest have reported a decline in subjects
resenting with ventricular fibrillation (VF) and a rise in the
revalence of pulseless electrical activity (16). Could older
CD recipients and those with more comorbidities be more
ikely to present with pulseless electrical activity, an arrhyth-
ia that would be unresponsive to ICD therapy? The
resent analysis is not able to provide answers to such
uestions. However, because we are still hoping to maxi-
ize our ability to identify the patient with the highest risk
f ICD-treatable ventricular arrhythmia, these findings
ould drive the design of future analyses that also reflect
ctual clinical practice.
Lee et al. (13) also report that heart failure burden was a
rominent determinant of mortality. In patients with
hronic heart failure and depressed LV systolic function,
r
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June 26, 2007:2416–8 Editorial Commentisk of sudden death is related to severity of heart failure
17). These observations are also supported by greater
enefit of the ICD with more advanced heart failure in the
IDS (Canadian Implantable Defibrillator Study) and
EFINITE (Defibrillators in Nonischemic Cardiomyopa-
hy Treatment Evaluation) trials (3,4). However, because
here is a 50-50 relationship between sudden death and
ump failure mortality (18), there is likely to be a turning
oint in heart failure severity where mortality from pump
ailure overtakes the likelihood of ICD-treatable arrhythmic
ortality. The randomized trials do not always report a
onsistent relationship between heart failure New York
eart Association (NYHA) functional class and ICD ben-
fit (no relationship observed in MADIT-II [Multicenter
utomatic Defibrillator Implantation Trial-II] [7], but in
he SCD-HeFT [Sudden Cardiac Death in Heart Failure
rial] NYHA functional class II did better than III [1]);
his inconsistency is likely related both to the differential
roportions of various NYHA classes between trials as well
s the vulnerability of the NYHA classification in clinical
ractice. A recent analysis from the MADIT-II pointed out
he logical link between longevity conferred by the ICD and
he burden of heart failure (19). The ICD recipients live
onger, but that also gives them time to develop more heart
ailure. Here the message from this real world analysis is in
greement with the randomized clinical trials: Implantation
f the ICD in a patient should be the marker for a renewed
ocus on prevention and management of heart failure in that
atient.
This analysis found that older age was also a determinant
f mortality even in patients in the 65- to 74-year age
ategory. These findings are at variance with the random-
zed ICD trials. In particular, CIDS reported a significantly
reater benefit of the ICD in patients aged over 70 years (3).
he fact remains that although the risk of SCD increases
ith age (20), there have been no randomized trials of ICD
mplantation conducted specifically in the elderly. Another
nding in the present analysis was a trend toward overall
mproved survival in ICD recipients, but this did not reach
tatistical significance. There were differences in the ICD
nd control groups that may have contributed toward
egating the mortality benefit of the ICD. The ICD
ecipients were older, and were more likely to have a history
f prior myocardial infarction, peripheral vascular disease,
nd renal disease—all conditions that can have independent
ffects on survival.
The analysis was not able to make a distinction between
rimary versus secondary indications for ICD implantation.
ased on the timing of case ascertainment and the fact that
3% of the patients in the study had prior diagnosis of
ardiac arrest, ventricular tachycardia (VT) or VF, the vast
ajority of patients are likely to have been implanted based
n a history of prior cardiac arrest or of low EF with
nducible VT. Therefore, these findings are unlikely to
eflect outcomes in primary prevention ICD recipients as
urrently identified. The authors have compared their re-ults to SCD-HeFT (1) but comparisons to the CIDS,
ASH (Cardiac Arrest Study Hamburg), and AVID (An-
iarrhythmics Versus Implantable Defibrillators) secondary
revention trials would be more relevant (3,5,8). The crude
ortality rate (7.8% at 1 year and 14% at 2 years) compares
ell with these 3 trials. However, the significantly lower
CD mortality benefit (2% at 2 years) among patients with
rior VT and cardiac arrest in the present analysis may have
een confounded by the likely low specificity and positive
redictive value of international classification of disease
odes for diagnoses such as sudden cardiac arrest and
entricular arrhythmia (20). The randomized trials did not
valuate the mortality burden of individual noncardiac
omorbidities.
As acknowledged by the authors, retrospective analyses
ased on administrative data sources can have significant
imitations, including undercoding as well as inadequate
pecificity. In addition, no information is available regarding
ode of death and clinical variables of importance such as
he use of beta-blockers and angiotensin-converting enzyme
nhibitors—factors that can independently contribute to-
ard decreasing both arrhythmic and nonarrhythmic mor-
ality (21,22).
The authors are to be commended for this real-world
nalysis in a large number of ICD recipients and control
ubjects that may well set the stage for subsequent such
nalyses reflecting actual clinical practice. Their findings
mphasize the need for a strong consideration of noncardiac
omorbidities in the care of a burgeoning and likely aging
CD population. An ICD implantation in a patient should
rompt specific attention toward prevention and manage-
ent of heart failure in that patient. Most importantly, the
ndings of this analysis provide much food for thought with
egard to the design and conduct of future real-world
tudies, including the evaluation of whether comorbidities
eed to be incorporated in the decision for ICD implanta-
ion, the need for comparisons between primary versus
econdary prevention, the availability of specific detail re-
arding clinical variables and mode of death, and the effects
f age on survival after ICD implantation.
eprint requests and correspondence: Dr. Sumeet S. Chugh,
ardiology Division, UHN-62, Oregon Health and Science Uni-
ersity, 3181 SW Sam Jackson Park Road, Portland, Oregon
7239. E-mail: chughs@ohsu.edu.
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